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Abstract
Clear cell renal cell carcinoma (ccRCC) represents the most common subtype of renal cell carcinoma (RCC). In spite of recent advances in the 
treatment armamentarium and outcomes with the combined use of immune checkpoint and angiogenesis inhibitors, prediction of responses and 
selection of patients remain a challenge. This is a case of ccRCC with recurrence to the liver 1 year following right radical nephrectomy, who 
rapidly progressed on frontline therapy with axitinib/pembrolizumab. The clinical course and targeted tumor sequencing findings are discussed. 
In addition to established clinical prognostication in RCC, several surrogate markers of efficacy or/and resistance have been proposed for immu-
notherapy or/and anti-angiogenic therapy. Since the majority of patients will still progress after these combinations, it is becoming increasingly 
important to develop robust predictive biomarkers to guide patient selection and sequencing of targeted therapies.
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Recent advances in the frontline therapy of advanced renal 
cell carcinoma (RCC) have led to novel combinations of 
agents targeting programmed death-1/programmed death-1 
ligand (PD-1/PD-L1) and the angiogenesis/vascular endo-
thelial growth factor receptor (VEGFR) pathway. The 
anti PD-1 monoclonal antibody (Mab) pembrolizumab 
(anti-PD-1) and the anti-PD-L1 avelumab were both FDA 
approved, each in combination with the VEGFR tyrosine 
kinase inhibitor (TKI) axitinib for previously untreated 
patients with advanced RCC, after improving the objective 
response rate (ORR), progression-free survival (PFS), or/and 
overall survival (OS), compared to the prior standard, suni-
tinib (1–3). This benefit was observed across all International 
Metastatic Renal Cell Carcinoma Database Consortium 
risk groups (favorable, intermediate, and poor risk) (1–4). In 
addition, the combination of the cytotoxic T-lymphocyte- 
associated protein 4 (CTLA-4) inhibitor ipilimumab and 
the PD-1 inhibitor nivolumab was approved for intermedi-
ate- and poor-risk, patients with advanced RCC (5). Nev-
ertheless, metastatic RCC remains a lethal disease overall, 
with a 5-year survival of approximately 10–20% (6), and a 
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required dose reduction of her axitinib to 3 mg twice daily 
due to fatigue, and experienced elevated thyroid stimulating 
hormone (TSH) of 16.5 mcIU/mL (normal free T4), which 
improved on levothyroxine. Unfortunately, after completing 
12 weeks on combination axitinib/pembrolizumab, repeat 
CT scans for assessment of response disclosed progression of 
liver metastases (Figure 1B).
A left hepatic lobe lesion was biopsied under CT guidance. 
Four core specimens were obtained. Deoxyribonucleic acid 
(DNA) and ribonucleic acid (RNA) were extracted from 
macrodissected, paraffin-embedded tumor of the patient 
using the Maxwell 16 instrument (Promega, Madison, WI) 
and RecoverAll Total Nucleid Acid Isolation Kit (Life 
Technologies, Walltham, MA), respectively. The extracted 
DNA and synthesized complementary DNA (cDNA) from 
the extracted RNA were amplified by the Oncomine Com-
prehensive Panel (OCP) and subjected to Next Generation 
Sequencing (NGS) using the Ion Torrent S5TM (Life Tech-
nologies), as previously described  (8). OCP was developed, 
and its performance characteristics were determined by the 
Clinical Genomics Laboratory, Englander Institute for Pre-
cision Medicine, Department of Pathology and Laboratory 
Medicine at Weill Cornell Medicine, New York-Presbyterian 
Hospital. OCP is approved by the New York State Depart-
ment of Health (NYS-DOH). Targeted tumor sequencing 
of patient’s CT-guided liver biopsy showed loss of func-
tion (pathogenic) mutations in von Hippel-Lindau (VHL) 
and BRCA1-associated protein (BAP1) genes, as well as 
copy-number loss of cyclin- dependent kinase inhibitor 2A 
(CDKN2A) (Table 1). Tumor purity (neoplastic content) of 
the tissue analyzed was 80%.
Discussion
Resistance to systemic therapies in advanced RCC, either 
intrinsic due to presence of resistant clones or acquired 
proportion of patients will still progress in spite of optimal 
therapy. At present, the majority of clinicians are not using 
any predictive biomarkers for treatment decision- making (7). 
A small proportion (10.9–12.4%) of advanced RCC patients 
treated with frontline PD-1/VEGFR-targeted combina-
tion therapy have demonstrated progressive disease as best 
response in the two major phase III studies of axitinib/
pembrolizumab and axitinib/avelumab, respectively (1–3). 
The underlying biology of this intrinsic resistance is poorly 
understood. Herein, the clinical and genomic evaluation of 
a case of advanced refractory RCC with lack of response 
to first-line axitinib/pembrolizumab is presented. The aim 
of molecular analysis of a liver metastasis from this patient 
was to assess for somatic alterations that could potentially be 
indicators of primary resistance to the combination or/and 
sensitivity to other agents.
Case Report
A 70-year-old woman presented with worsening right upper 
quadrant pain of 2 weeks duration, associated with anorexia 
and 10 lb weight loss. She had a history of right nephrectomy 
13 months earlier for a grade 3, stage III pT3aNxM0 clear 
cell renal cell carcinoma (ccRCC), with extension to the renal 
vein and uninvolved margins; however, she did not follow up 
after surgery. No family history of cancer was reported. A 
computed tomography (CT) scan of her abdomen and pel-
vis disclosed hepatomegaly and several hypodense lesions 
throughout the liver parenchyma consistent with liver metas-
tases (Figure 1A). Labs were remarkable for a hemoglobin 
level of 11.2 g/dL and an elevated serum lactate dehydroge-
nase level of 612 U/L.
The patient was started on pembrolizumab 200 mg intra-
venously every 3 weeks and axitinib 5 mg orally twice daily 
as first-line therapy for her recurrent/metastatic disease after 
completing full restaging, which was otherwise negative. She 
A B
Figure 1: (A) Computed tomography (CT) abdomen and pelvis (pre-treatment) showing hepatomegaly and several hypodense 
lesions throughout the liver parenchyma consistent with liver metastases. (B) CT abdomen and pelvis (post-treatment) showing 
enlargement of existing lesions and new hepatic metastases.
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expression scores from a 43-gene signature were lower in 
patients with BAP1-mutated tumors, suggesting that BAP1 
loss correlates with lower angiogenic signaling and worse 
outcomes after treatment with TKIs (20). Overall, both 
BAP1 and VHL deleterious/loss of function mutations were 
identified in hyperprogressive tumors post anti-PD-1 treat-
ment, suggesting a potential involvement in the development 
of resistance (21).
CDKN2A is a ubiquitously expressed gene that encodes 
two other key genes, the INK4 family member p16 
(p16INK4a) and p14ARF, both of which act as tumor sup-
pressors regulating the cell cycle. CDKN2A gene aberra-
tions, including mutations, hypermethylation, or deletions, 
occur in approximately 16% of ccRCCs (10), with loss of the 
chromosome 9p region encoding CDKN2A being the most 
frequent event (12%) in these cases (10). CDKN2A loss is 
associated with a higher tumor stage at diagnosis (22) and 
predicts shorter OS across all TCGA RCC subtypes (10). 
Patients with tumors that harbor chromosomal CDKN2A 
loss are frequently characterized by resistance to immuno-
therapy, which has been mechanistically explained, at least 
partially, by a concurrent deletion of the interferon-gamma 
(IFNγ) signaling pathway gene JAK2 (23). In addition, 
copy-number variations of CDKN2A or/and other genes 
in the CDK4 pathway (CDK4, CCND1) are associated 
with innate resistance to anti-PD-1 therapy in patients with 
advanced melanoma, which can be reversed with addition 
of CDK4/6 inhibitors to anti-PD-1 antibodies (24). Inter-
estingly, CDK4/6 inhibitors have shown activity in RCC in 
vitro, and the combination of abemaciclib with sunitinib 
resulted in a dramatic reduction in tumor sizes in a RCC 
mouse model (25). A phase 1 trial of these two agents is 
currently ongoing in progressing patients with metastatic 
ccRCC (NCT03905889).
Collectively, treatment of RCC patients with disease pro-
gression after axitinib/pembrolizumab or axitinib/avelumab 
is complex, and the current expert consensus agreement is 
on the use of another VEGFR pathway inhibitor, cabozan-
tinib, which also has activity against MET, AXL, and RET 
kinases  (7). A potential predictive value of T-effector gene 
expression and angiogenesis signatures has been supported 
from exploratory biomarker analyses of PD-1/PD-L1 plus 
after initial tumor regression can directly impact the clinical 
course and additional treatment approach of these patients 
in contemporary practice.
While the underlying mechanisms are a field of ongoing 
investigation, numerous studies have identified molecular 
alterations in primary and metastatic RCC tumors that may 
be contributing to the development of resistance (9).
The VHL gene is the most frequently mutated gene in 
the majority (80–90%) of sporadic RCCs (9–11). Mechanis-
tically, the loss of VHL protein function leads to the accu-
mulation of hypoxia-inducible factor (HIF) that promotes 
angiogenesis and tumor growth (9, 11). It has been found that 
the effect of VHL mutation on responses to VEGFR TKIs in 
patients with metastatic ccRCC is minimal, if  any (12). Fur-
thermore, although VHL is an inducer of PD-L1 through 
upregulation of HIF-2α (13), PD-L1 immunohistochemical 
expression status had no effect on ORR and PFS in neither 
of the two large phase 3 trials testing the PD-1/PD-L1 plus 
VEGFR pathway inhibitors combination (1–3). Other stud-
ies have demonstrated that overexpression and activation of 
the receptor tyrosine kinases MET and AXL due to VHL 
inactivation is implicated in resistance to VEGFR-targeted 
therapies (14). Specifically, combination of axitinib with the 
c-met inhibitor crizotinib in RCC patient-derived xenograft 
models resulted in decreased tumor microvessel density, 
growth inhibition, and improved survival (15).
The BAP1 gene is mutated in different cancers, includ-
ing ccRCC in up to 11% of cases (10). The resultant loss 
of function of this tumor suppressor was associated with 
more aggressive morphologic features (16) and decreased 
OS both in The Cancer Genome Atlas (TCGA) RCC 
cohort and within the ccRCC group (10). Besides its prog-
nostic relevance, BAP1 loss in non-RCC tumors was cor-
related with upregulation of suppressive immune gene 
responses, for example, HLA-DR, CD38, and CD74 (uveal 
 melanoma)  (17), and the promotion of an inflammatory 
tumor microenvironment (peritoneal mesothelioma) (18). 
Interestingly, an integrated biomarker analysis of 412 RCC 
patients who were treated on the phase 3 COMPARZ trial 
comparing pazopanib versus sunitinib (19) demonstrated 
that those with tumors harboring mutated BAP1 had infe-
rior OS compared to wild-type ones (20). Angiogenesis gene 
Table 1: Genomic alterations (pathogenic) of liver metastasis from clear cell renal cell carcinoma.
Gene Alteration Type VAF
VHL c.162_163insCG, p.Glu55Argfs*13 Mutation – frameshift insertion 32.8%
BAP1 c.509T>G, p.Phe170Cys Mutation – missense 42.6%
CDKN2A loss Copy number alteration – loss N/A
VAF: variant allele frequency, N/A: not applicable, VHL, von Hippel-Lindau, BAP1, BRCA1-associated protein, CDKN2A, cyclin-dependent 
kinase inhibitor 2A.
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VEGFR TKI  combination studies (26–28); however, this 
is largely hypothesis-generating and not ready for clinical 
use. It also remains ill-defined as to how potential genomic 
biomarkers could be combined with the established clini-
cal prognostication tools (the IMDC, the Cleveland Clinic 
Foundation CCF model, the International Kidney Cancer 
Working Group IKCWG model, the French model, and 
the Memorial Sloan-Kettering Cancer Center model) (4) to 
improve our prediction of effective therapies. In phase 2 and 
3 studies of the anti-PD-L1 Mab atezolizumab combined 
with the anti-VEGF-A Mab bevacizumab, expression of 
angiogenesis genes was enriched in patients with favorable 
risk, compared to those with intermediate and poor risk 
according to the MSKCC risk stratification model (28).
Conclusion
This case of advanced refractory RCC with clinical and 
genomic evaluation highlights an unmet need for better 
characterizing the underlying biology of treatment-resistant 
RCC in order to improve our ability to conduct biology- and 
biomarker- driven trials to help guide selection of the right 
drug, for the right target, in the right patient, at the right 
time.
Conflict of interest
The author declares no potential conflicts of interest with 
respect to research, authorship, and/or publication of this 
article.
References
1. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, 
et al. Pembrolizumab plus axitinib versus sunitinib for advanced 
renal-cell carcinoma. N Engl J Med. 2019 Mar 21;380(12):1116–
27. http://dx.doi.org/10.1056/NEJMoa1816714
2. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell 
MT, et al. Avelumab plus axitinib versus sunitinib for advanced 
renal-cell carcinoma. N Engl J Med. 2019 Mar 21;380(12):1103–
15. http://dx.doi.org/10.1056/NEJMoa1816047
3. Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, 
Venugopal B, et al. Updated efficacy results from the JAVELIN 
renal 101 trial: First-line avelumab plus axitinib versus sunitinib 
in patients with advanced renal cell carcinoma. Ann Oncol. 2020 
Apr 24. pii: S0923-7534(20)39308-X. http://dx.doi.org/10.1016/j.
annonc.2020.04.010
4. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, 
Vaishampayan UN, et al. External validation and compari-
son with other models of the International Metastatic Renal-
Cell Carcinoma Database Consortium prognostic model: A 
population- based study. Lancet Oncol. 2013 Feb;14(2):141–8. 
http://dx.doi.org/10.1016/S1470-2045(12)70559-4
5. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, 
Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab 
versus sunitinib in advanced renal-cell carcinoma. N Engl J 
Med. 2018 Apr 5;378(14):1277–90. http://dx.doi.org/10.1056/
NEJMoa1712126
6. NIH, National Cancer Institute, Surveillance Epidemiology and 
End Results Program. Cancer Stat Facts: Kidney and Renal 
Pelvis Cancer [Internet]. [Accessed 2020 May 1]. Available from: 
https://seer.cancer.gov/statfacts/html/kidrp.html
7. Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, 
et al. The society for immunotherapy of cancer consensus state-
ment on immunotherapy for the treatment of advanced renal cell 
carcinoma (RCC). J Immunother Cancer. 2019 Dec 20;7(1):354. 
http://dx.doi.org/10.1186/s40425-019-0813-8
8. Park K, Tran H, Eng KW, Ramazanoglu S, Marrero Rolon RM, 
Scognamiglio T, et al. Performance characteristics of a targeted 
sequencing platform for simultaneous detection of single nucle-
otide variants, insertions/deletions, copy number alterations, 
and gene fusions in cancer genome. Arch Pathol Lab Med. 2020 
Feb 11. http://dx.doi.org/10.5858/arpa.2019-0162-OA
9. Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, 
Kolenko  VM. Resistance to systemic therapies in clear cell 
renal cell carcinoma: Mechanisms and management strate-
gies. Mol Cancer Ther. 2018 Jul;17(7):1355–64. http://dx.doi.
org/10.1158/1535-7163.MCT-17-1299
10. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, 
Reznik E, et al. The cancer genome atlas comprehensive 
molecular characterization of  renal cell carcinoma. Cell 
Rep. 2018 Apr 3;23(1):313–26.e5. http://dx.doi.org/10.1016/j.
celrep.2018.03.075
11. Hsieh JJ, Le VH, Oyama T, Ricketts CJ, Ho TH, Cheng EH. 
Chromosome 3p loss-orchestrated VHL, HIF, and epigenetic 
deregulation in clear cell renal cell carcinoma. J Clin Oncol. 
2018 Oct 29:JCO2018792549. http://dx.doi.org/10.1200/
JCO.2018.79.2549
12. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, 
et al. von Hippel-Lindau gene status and response to vascular 
endothelial growth factor targeted therapy for metastatic clear 
cell renal cell carcinoma. J Urol. 2008 Sep;180(3):860–5; discus-
sion 865–6.
13. Messai Y, Gad S, Noman MZ, Le Teuff G, Couve S, Janji  B, 
et al. Renal cell carcinoma programmed death-ligand 1, a new 
direct target of hypoxia-inducible factor-2 alpha, is regulated 
by von Hippel-Lindau gene mutation status. Eur Urol. 2016 
Oct;70(4):623–32. http://dx.doi.org/10.1016/j.eururo.2015.11.029.
14. Rankin EB, Fuh KC, Castellini L, Viswanathan K, Finger EC, 
Diep AN, et al. Direct regulation of GAS6/AXL signaling by 
HIF promotes renal metastasis through SRC and MET. Proc 
Natl Acad Sci U S A. 2014;111:13373–8. https://doi.org/10.1073/
pnas.1404848111
15. Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, 
Shen L, Ku S, et al. Combination strategy targeting VEGF and 
HGF/c-met in human renal cell carcinoma models. Mol Cancer 
Ther. 2015;14:101–10. https://doi.org/10.1158/1535-7163.
MCT-14-0094
16. Gu YF, Cohn S, Christie A, McKenzie T, Wolff  N, Do QN, et al. 
Modeling renal cell carcinoma in mice: Bap1 and Pbrm1 inacti-
vation drive tumor grade. Cancer Discov. 2017 Aug;7(8):900–17. 
http://dx.doi.org/10.1158/2159-8290.CD-17-0292
17. Figueiredo CR, Kalirai H, Sacco JJ, Azevedo RA, Duckworth A, 
Slupsky JR, et al. Loss of BAP1 expression is associated with an 
immunosuppressive microenvironment in uveal melanoma, with 
implications for immunotherapy development. J Pathol. 2020 
Apr;250(4):420–39. http://dx.doi.org/10.1002/path.5384
Advanced refractory RCC: clinicomolecular findings
 Journal of Kidney Cancer and VHL 2020; 7(1): 7–11 11
susceptibility to immunotherapy resistance. J Natl Cancer Inst. 
2018 Jun 1;110(6):677–81. http://dx.doi.org/10.1093/jnci/djx271
24. Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, et al. Genetic aber-
rations in the CDK4 pathway are associated with innate resis-
tance to PD-1 blockade in Chinese patients with non-cutaneous 
melanoma. Clin Cancer Res. 2019 Nov 1;25(21):6511–23. http://
dx.doi.org/10.1158/1078-0432.CCR-19-0475
25. Small J, Washburn E, Millington K, Zhu J, Holder SL. The 
addition of abemaciclib to sunitinib induces regression of 
renal cell carcinoma xenograft tumors. Oncotarget. 2017 Jul 
27;8(56):95116–34. http://dx.doi.org/10.18632/oncotarget.19618
26. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, 
Escudier B, et al. Clinical activity and molecular correlates of 
response to atezolizumab alone or in combination with bev-
acizumab versus sunitinib in renal cell carcinoma. Nat Med. 
2018;24(6):749–57. http://dx.doi.org/10.1038/s41591-018-0235-z
27. Choueiri TK, Albiges L, Haanen JBAG, Larkin JMG, 
Uemura M, Pal SK, et al. Biomarker analyses from JAVELIN 
renal 101: Avelumab + axitinib (A+Ax) versus sunitinib 
(S) in advanced renal cell carcinoma (aRCC). J Clin Oncol. 
2019;May 20;37(15_Suppl):101–1. http://dx.doi.org/10.1200/
JCO.2019.37.15_suppl.101
28. Rini B, Huseni M, Atkins MB, McDermott DF, Powles TB, 
Escudier B, et al. Molecular correlates differentiate response 
to atezolizumab + bevacizumab vs sunitinib. Ann Oncol. 2018 
October 20;29(Suppl_8):LBA31. https://doi.org/10.1093/
annonc/mdy424.037
18. Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, et al. 
BAP1 haploinsufficiency predicts a distinct immunogenic class 
of malignant peritoneal mesothelioma. Genome Med. 2019 Feb 
18;11(1):8. http://dx.doi.org/10.1186/s13073-019-0620-3
19. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, 
et al. Pazopanib versus sunitinib in metastatic renal-cell carci-
noma. N Engl J Med. 2013 Aug 22;369(8):722–31. http://dx.doi.
org/10.1056/NEJMoa1303989
20. Voss MH, Kuo F, Chen D, Marker M, Patel P, Redzematovic A, 
et al. Integrated biomarker analysis for 412 renal cell can-
cer (RCC) patients (pts) treated on the phase 3 COMPARZ 
trial: Correlating common mutation events in PBRM1 and 
BAP1 with angiogenesis expression signatures and outcomes 
on tyrosine kinase inhibitor (TKI) therapy. J Clin Oncol. 
2017 May 20;35(15_Suppl):4523–3. http://dx.doi.org/10.1200/
JCO.2017.35.15_suppl.4523
21. Xiong D, Wang Y, Singavi AK, Mackinnon AC, George B, 
You M. Immunogenomic landscape contributes to hyperpro-
gressive disease after anti-PD-1 immunotherapy for cancer. 
iScience. 2018 Nov 30;9:258–77. http://dx.doi.org/10.1016/j.
isci.2018.10.021
22. Nouhaud FX, Blanchard F, Sesboue R, Flaman JM, 
Sabourin  JC, Pfister C. Clinical relevance of gene copy num-
ber variation in metastatic clear cell renal cell carcinoma. Clin 
Genitourin Cancer. 2018 Aug;16(4):e795–805. http://dx.doi.
org/10.1016/j.clgc.2018.02.013
23. Horn S, Leonardelli S, Sucker A, Schadendorf D, Griewank KG, 
Paschen A. Tumor CDKN2A-associated JAK2 loss and 
